IL-22/IL-22R1 pathway enhances cholangiocarcinoma progression via ERK1/2 activation

Figure 8 The ERK inhibitor can block the effects of IL-22 on the anti-apoptotic capacity of cholangiocarcinoma cells. A: Flow cytometry apoptosis images of HuCCT1 and RBE cells from different treatment groups, along with the results of quantitative analysis comparing each group; B: TUNEL assay images of HuCCT1 and RBE cells from different treatment groups, along with the results of quantitative analysis comparing each group; C: Western blot images of P-ERK1/2, BAX, and Bcl2 in HuCCT1 and RBE cells from different treatment groups, along with the analysis results of Western blot quantification comparing the groups. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, ^dP < 0.0001. NC: Negative control.